Figure 3.
Kaplan-Meier curve of progression free survival in patients treated with pembrolizumab. The median progression free survival time was 5.7 months (95% CI: 4.37—not reached).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.